Literature DB >> 17442014

Progress in vaccine development against Helicobacter pylori.

Ann-Mari Svennerholm1, Anna Lundgren.   

Abstract

Based on the very high prevalence of diseases caused by Helicobacter pylori, particularly in the developing world, and the rapid emergence of antibiotic resistance among clinical isolates, there is a strong rationale for an effective vaccine against H. pylori. In this review we describe recent promising candidate vaccines and prophylactic or therapeutic immunization strategies for use against H. pylori, as well as studies to identify immune responses that are related to protection in experimental animals. We also describe identification of different types of immune responses that may be related to protection against symptoms based on comparisons of H. pylori-infected patients with duodenal ulcers or gastric cancer and asymptomatic carriers. We conclude that there is still a strong need to clarify the main protective immune mechanisms against H. pylori as well as to identify a cocktail of strong protective antigens, or recombinant bacterial strains that express such antigens, that could be administered by a regimen that gives rise to effective immune responses in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442014     DOI: 10.1111/j.1574-695X.2007.00237.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  10 in total

1.  Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase.

Authors:  Carl-Fredrik Flach; Anna Karin Östberg; Anne-Therese Nilsson; Rene De Waal Malefyt; Sukanya Raghavan
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 2.  Vaccinating against Helicobacter pylori infection.

Authors:  Steven J Czinn; Thomas Blanchard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02-08       Impact factor: 46.802

3.  Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach.

Authors:  Sukanya Raghavan; Anna Karin Ostberg; Carl-Fredrik Flach; Annelie Ekman; Margareta Blomquist; Cecil Czerkinsky; Jan Holmgren
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

4.  A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.

Authors:  Louise Sjökvist Ottsjö; Carl-Fredrik Flach; John Clements; Jan Holmgren; Sukanya Raghavan
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

5.  Defining the Roles of IFN-γ and IL-17A in Inflammation and Protection against Helicobacter pylori Infection.

Authors:  Louise Sjökvist Ottsjö; Carl-Fredrik Flach; Staffan Nilsson; Rene de Waal Malefyt; Anna K Walduck; Sukanya Raghavan
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

6.  Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination.

Authors:  Iris Bosschem; Jagadeesh Bayry; Ellen De Bruyne; Kim Van Deun; Annemieke Smet; Griet Vercauteren; Richard Ducatelle; Freddy Haesebrouck; Bram Flahou
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

7.  DNA vaccine containing Flagellin A gene induces significant immune responses against Helicobacter pylori infection: An in vivo study.

Authors:  Hossein Ansari; Maryam Tahmasebi-Birgani; Mahdi Bijanzadeh
Journal:  Iran J Basic Med Sci       Date:  2021-06       Impact factor: 2.699

Review 8.  Helicobacter pylori infection in developing countries: the burden for how long?

Authors:  Barik A Salih
Journal:  Saudi J Gastroenterol       Date:  2009 Jul-Sep       Impact factor: 2.485

9.  Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.

Authors:  Nancy A Summerton; Richard W Welch; Laureano Bondoc; Huei-Hsiung Yang; Brett Pleune; Naryaswamy Ramachandran; Andrea M Harris; Desiree Bland; W James Jackson; Sukjoon Park; John D Clements; Gary S Nabors
Journal:  Vaccine       Date:  2009-11-06       Impact factor: 3.641

10.  Epidemiological aspects of gastric adenocarcinoma: are predictive diagnostics and targeted preventive measures possible?

Authors:  Krister Sjödahl; Jesper Lagergren
Journal:  EPMA J       Date:  2010-07-22       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.